The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment
Open accessAbstract
The BCL2 family plays important roles in acute myeloid leukemia (AML). Venetoclax, a selective BCL2 inhibitor, has received FDA approval for the treatment of AML. However, drug resistance ensues after prolonged treatment, highlighting the need for a greater understanding of the underlying mechanisms. Using a genome-wide CRISPR/Cas9 screen in human AML, we identified genes whose inactivation sensitizes AML blasts to venetoclax. Genes involved in mitochondrial organization and function were significantly depleted throughout our screen, including the mitochondrial chaperonin CLPB. We demonstrated that CLPB is upregulated in human AML, it is further induced upon acquisition of venetoclax resistance, and its ablation sensitizes AML to venetoclax. Mechanistically, CLPB maintains the mitochondrial cristae structure via its interaction with the cristae-shaping protein OPA1, whereas its loss promotes apoptosis by inducing cristae remodeling and mitochondrial stress responses. Overall, our data suggest that targeting mitochondrial architecture may provide a promising approach to circumvent venetoclax resistance. Significance: A genome-wide CRISPR/Cas9 screen reveals genes involved in mitochondrial biological processes participate in the acquisition of venetoclax resistance. Loss of the mitochondrial protein CLPB leads to structural and functional defects of mitochondria, hence sensitizing AML cells to apoptosis. Targeting CLPB synergizes with venetoclax and the venetoclax/azacitidine combination in AML in a p53-independent manner. See related commentary by Savona and Rathmell, p. 831. This article is highlighted in the In This Issue feature, p. 813
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., & Wang, X. (1997) · Cell · doi:10.1016/s0092-8674(00)80434-1 · Cited by 7,289
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637
An APAF-1·Cytochrome c Multimeric Complex Is a Functional Apoptosome That Activates Procaspase-9
Zou, H., Li, Y., Liu, X., & Wang, X. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11549 · Cited by 2,090
Mitochondrial DNA stress primes the antiviral innate immune response
West, A. P., Khoury-Hanold, W., Staron, M., Tal, M. C., Pineda, C. M., Lang, S. M., Bestwick, M., Duguay, B. A., Raimundo, N., MacDuff, D. A., et al. (2015) · Nature · doi:10.1038/nature14156 · Cited by 1,975
DiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825
BCL-2 FAMILY: Regulators of Cell Death
Chao, D. T., & Korsmeyer, S. J. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.395 · Cited by 1,685
OPA1 Controls Apoptotic Cristae Remodeling Independently from Mitochondrial Fusion
Frezza, C., Cipolat, S., Martins de Brito, O., Micaroni, M., Beznoussenko, G. V., Rudka, T., Bartoli, D., Polishuck, R. S., Danial, N. N., De Strooper, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.06.025 · Cited by 1,673
High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.
Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K. R., MacLeod, G., Mis, M., Zimmermann, M., Fradet-Turcotte, A., Sun, S., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.015 · Cited by 1,571
Lagadinou, E. D., Sach, A., Callahan, K., Rossi, R. M., Neering, S. J., Minhajuddin, M., Ashton, J. M., Pei, S., Grose, V., O’Dwyer, K. M., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2012.12.013 · Cited by 1,399
A Distinct Pathway Remodels Mitochondrial Cristae and Mobilizes Cytochrome c during Apoptosis
Scorrano, L., Ashiya, M., Buttle, K., Weiler, S., Oakes, S. A., Mannella, C. A., & Korsmeyer, S. J. (2002) · Developmental Cell · doi:10.1016/s1534-5807(01)00116-2 · Cited by 1,072
Konopleva, M., Pollyea, D. A., Potluri, J., Chyla, B., Hogdal, L., Busman, T., McKeegan, E., Salem, A. H., Zhu, M., Ricker, J. L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0313 · Cited by 1,064
Quirós, P. M., Prado, M. A., Zamboni, N., D’Amico, D., Williams, R. W., Finley, D., Gygi, S. P., & Auwerx, J. (2017) · Journal of Cell Biology · doi:10.1083/jcb.201702058 · Cited by 832 · cited 4×
“Considering our previous results and given that ATF4 has been identified as a key regulator of the mitochondrial stress response in mammals (30), we speculated that CLPB-deficient AML cells are under mitochondrial stress.”
BackgroundMethodResultInfluentialPernas, L., & Scorrano, L. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105011 · Cited by 817
The i -AAA protease YME1L and OMA1 cleave OPA1 to balance mitochondrial fusion and fission
Anand, R., Wai, T., Baker, M. J., Kladt, N., Schauss, A. C., Rugarli, E., & Langer, T. (2014) · Journal of Cell Biology · doi:10.1083/jcb.201308006 · Cited by 812
Campos, L., Rouault, J., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J., & Guyotat, D. (1993) · Blood · doi:10.1182/blood.v81.11.3091.3091 · Cited by 784
Pollyea, D. A., Stevens, B. M., Jones, C. L., Winters, A., Pei, S., Minhajuddin, M., D’Alessandro, A., Culp-Hill, R., Riemondy, K. A., Gillen, A. E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0233-1 · Cited by 778 · cited 1×
“Recently, Pollyea and colleagues demonstrated that the FDA-approved combined treatment of venetoclax with azacitidine disrupts the tricarboxylic acid cycle in LSCs of patients with AML and that relapsed patients with AML remodel their metabolism (45, 46).”
BackgroundSelective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Pan, R., Hogdal, L. J., Benito, J. M., Bucci, D., Han, L., Borthakur, G., Cortes, J., DeAngelo, D. J., Debose, L., Mu, H., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0609 · Cited by 735
DiNardo, C. D., Pratz, K. W., Letai, A., Jonas, B. A., Wei, A. H., Thirman, M., Arellano, M., Frattini, M. G., Kantarjian, H., Popovic, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30010-x · Cited by 722
Mechanisms of cytochrome c release by proapoptotic BCL-2 family members
Scorrano, L., & Korsmeyer, S. J. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00615-6 · Cited by 716
Surviving Stress: Modulation of ATF4-Mediated Stress Responses in Normal and Malignant Cells
Wortel, I. M. N., van der Meer, L. T., Kilberg, M. S., & van Leeuwen, F. N. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.07.003 · Cited by 609
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells
Jones, C. L., Stevens, B. M., D'Alessandro, A., Reisz, J. A., Culp-Hill, R., Nemkov, T., Pei, S., Khan, N., Adane, B., Ye, H., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.005 · Cited by 585
Mitochondria, Bioenergetics and Apoptosis in Cancer
Burke, P. J. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.10.006 · Cited by 432
Lee, S., Sowa, M. E., Watanabe, Y.-H., Sigler, P. B., Chiu, W., Yoshida, M., & Tsai, F. T. F. (2003) · Cell · doi:10.1016/s0092-8674(03)00807-9 · Cited by 414
The MDM2-p53 pathway revisited
Subhasree, N., Jiangjiang, Q., Kalkunte, S., Minghai, W., & Ruiwen, Z. (2013) · The Journal of Biomedical Research · doi:10.7555/jbr.27.20130030 · Cited by 414
Ramsey, H. E., Fischer, M. A., Lee, T., Gorska, A. E., Arrate, M. P., Fuller, L., Boyd, K. L., Strickland, S. A., Sensintaffar, J., Hogdal, L. J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0140 · Cited by 379
Pathways and mechanisms of venetoclax resistance
Bose, P., Gandhi, V., & Konopleva, M. (2017) · Leukemia & Lymphoma · doi:10.1080/10428194.2017.1283032 · Cited by 302
Pan, R., Ruvolo, V., Mu, H., Leverson, J. D., Nichols, G., Reed, J. C., Konopleva, M., & Andreeff, M. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.003 · Cited by 300
How do Bax and Bak lead to permeabilization of the outer mitochondrial membrane?
Antignani, A., & Youle, R. J. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.10.004 · Cited by 277
The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias
Tzifi, F., Economopoulou, C., Gourgiotis, D., Ardavanis, A., Papageorgiou, S., & Scorilas, A. (2012) · Advances in Hematology · doi:10.1155/2012/524308 · Cited by 254
Bogenberger, J. M., Kornblau, S. M., Pierceall, W. E., Lena, R., Chow, D., Shi, C.-X., Mantei, J., Ahmann, G., Gonzales, I. M., Choudhary, A., et al. (2014) · Leukemia · doi:10.1038/leu.2014.44 · Cited by 200
Self-citationPotential mechanisms of resistance to venetoclax and strategies to circumvent it
Tahir, S. K., Smith, M. L., Hessler, P., Rapp, L. R., Idler, K. B., Park, C. H., Leverson, J. D., & Lam, L. T. (2017) · BMC Cancer · doi:10.1186/s12885-017-3383-5 · Cited by 195
BH3 profiling in whole cells by fluorimeter or FACS
Ryan, J., & Letai, A. (2013) · Methods · doi:10.1016/j.ymeth.2013.04.006 · Cited by 174
Gilquin, B., Taillebourg, E., Cherradi, N., Hubstenberger, A., Gay, O., Merle, N., Assard, N., Fauvarque, M.-O., Tomohiro, S., Kuge, O., et al. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00007-10 · Cited by 171
Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia
Reyna, D. E., Garner, T. P., Lopez, A., Kopp, F., Choudhary, G. S., Sridharan, A., Narayanagari, S.-R., Mitchell, K., Dong, B., Bartholdy, B. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.001 · Cited by 163
Self-citationEnhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1
Teh, T.-C., Nguyen, N.-Y., Moujalled, D. M., Segal, D., Pomilio, G., Rijal, S., Jabbour, A., Cummins, K., Lackovic, K., Blombery, P., et al. (2018) · Leukemia · doi:10.1038/leu.2017.243 · Cited by 159
Bogenberger, J. M., Delman, D., Hansen, N., Valdez, R., Fauble, V. D. S., Mesa, R. A., & Tibes, R. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.910657 · Cited by 152
Self-citationThe changing shape of mitochondrial apoptosis
Wasilewski, M., & Scorrano, L. (2009) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2009.03.007 · Cited by 136
Wortmann, S. B., Ziętkiewicz, S., Kousi, M., Szklarczyk, R., Haack, T. B., Gersting, S. W., Muntau, A. C., Raković, A., Renkema, G. H., Rodenburg, R. J., et al. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2014.12.013 · Cited by 134
Gerdes, F., Tatsuta, T., & Langer, T. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.09.015 · Cited by 134
AFG3L2 supports mitochondrial protein synthesis and Purkinje cell survival
Almajan, E.-R., Richter‐Dennerlein, R., Paeger, L., Martinelli, P., Barth, E., Decker, T., Larsson, N., Kloppenburg, P., Langer, T., & Rugarli, E. I. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64604 · Cited by 114
Combined venetoclax and alvocidib in acute myeloid leukemia
Bogenberger, J. M., Whatcott, C. J., Hansen, N., Delman, D., Shi, C.-X., Kim, W., Haws, H., Soh, K. K., Lee, Y. S., Peterson, P. W., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22284 · Cited by 97
Self-citationMultifunctional Mitochondrial AAA Proteases
Glynn, S. E. (2017) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2017.00034 · Cited by 81
Röttgers, K., Zufall, N., Guiard, B., & Voos, W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207152200 · Cited by 79
Guo, Y. P., Strickland, S. A., Mohan, S. R., Li, S., Bosompem, A., Vickers, K. C., Zhao, S., Sheng, Q., & Kim, A. S. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1272680 · Cited by 71
ATF4 orchestrates a program of BH3-only protein expression in severe hypoxia
Pike, L., Phadwal, K., Simon, A. K., & Harris, A. L. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-1975-3 · Cited by 39
HAX-1 inhibits apoptosis in prostate cancer through the suppression of caspase-9 activation
Yan, J., MA, C., Cheng, J., LI, Z., & Liu, C. (2015) · Oncology Reports · doi:10.3892/or.2015.4202 · Cited by 32
Screening and Evaluation of Small Organic Molecules as ClpB Inhibitors and Potential Antimicrobials
Martín, I., Underhaug, J., Celaya, G., Moro, F., Teigen, K., Martı́nez, A., & Muga, A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400499k · Cited by 23
Abrahão, J., Mokry, D. Z., & Ramos, C. H. I. (2017) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2017.00060 · Cited by 11
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
The cell biology of mitochondrial membrane dynamics
Giacomello, M., Pyakurel, A., Glytsou, C., & Scorrano, L. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0210-7 · Cited by 1,550
Self-citationDiNardo, C. D., Tiong, I. S., Quaglieri, A., MacRaild, S., Loghavi, S., Brown, F. C., Thijssen, R., Pomilio, G., Ivey, A., Salmon, J. M., et al. (2020) · Blood · doi:10.1182/blood.2019003988 · Cited by 679
Self-citationThe manipulation of apoptosis for cancer therapy using BH3-mimetic drugs
Diepstraten, S. T., Anderson, M. A., Czabotar, P. E., Lessene, G., Strasser, A., & Kelly, G. L. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00407-4 · Cited by 346
Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells
Stevens, B. M., Jones, C. L., Pollyea, D. A., Culp-Hill, R., D’Alessandro, A., Winters, A., Krug, A., Abbott, D., Goosman, M., Pei, S., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00126-z · Cited by 310
Metadata
- Authors
- Chen, X., Glytsou, C., Zhou, H., Narang, S., Reyna, D. E., Lopez, A., Sakellaropoulos, T., Gong, Y., Kloetgen, A., Yap, Y. S., Wang, E., Gavathiotis, E., Tsirigos, A., Tibes, R., & Aifantis, I.
- Venue
- Cancer Discovery
- Published
- 2019-07-01
- Volume
- 9
- Issue
- 7
- Pages
- 890-909
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2943489262
- Cited by
- 348
- References
- 48
- FWCI
- 19.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.